HUE063428T2 - PI3K P-DELTA 110 gátlószerei rák kezelésében vírusok bejuttatására történõ alkalmazásra - Google Patents
PI3K P-DELTA 110 gátlószerei rák kezelésében vírusok bejuttatására történõ alkalmazásraInfo
- Publication number
- HUE063428T2 HUE063428T2 HUE17701004A HUE17701004A HUE063428T2 HU E063428 T2 HUE063428 T2 HU E063428T2 HU E17701004 A HUE17701004 A HU E17701004A HU E17701004 A HUE17701004 A HU E17701004A HU E063428 T2 HUE063428 T2 HU E063428T2
- Authority
- HU
- Hungary
- Prior art keywords
- pi3k
- viruses
- delta
- inhibitors
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277002P | 2016-01-11 | 2016-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE063428T2 true HUE063428T2 (hu) | 2024-01-28 |
Family
ID=57861179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17701004A HUE063428T2 (hu) | 2016-01-11 | 2017-01-11 | PI3K P-DELTA 110 gátlószerei rák kezelésében vírusok bejuttatására történõ alkalmazásra |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11351209B2 (hu) |
| EP (1) | EP3402468B1 (hu) |
| CN (1) | CN109219450A (hu) |
| ES (1) | ES2959563T3 (hu) |
| HK (1) | HK1258235A1 (hu) |
| HR (1) | HRP20231299T1 (hu) |
| HU (1) | HUE063428T2 (hu) |
| PL (1) | PL3402468T3 (hu) |
| RS (1) | RS64678B1 (hu) |
| WO (1) | WO2017122000A1 (hu) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368246B (zh) * | 2021-05-12 | 2023-05-26 | 中山大学 | 一种增效的抗肿瘤药物 |
| WO2022252044A1 (en) * | 2021-05-31 | 2022-12-08 | Suzhou Singleron Biotechnologies Co., Ltd. | Drug repurposing to treat primary lung adenocarcinoma based on deep embeddings of single-cell sequencing analysis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102439012A (zh) | 2009-03-24 | 2012-05-02 | 吉里德卡利斯托加公司 | 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法 |
| SG188550A1 (en) * | 2010-09-24 | 2013-04-30 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| US20120100109A1 (en) * | 2010-10-26 | 2012-04-26 | Xiaoliu Zhang | Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors |
| CN103110939A (zh) | 2012-10-23 | 2013-05-22 | 郑州大学 | 诱导肿瘤特异性免疫的疫苗及其应用 |
| KR20150079745A (ko) | 2012-11-08 | 2015-07-08 | 리젠 파마슈티컬스 소시에떼 아노님 | Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물 |
| GB201405834D0 (en) | 2014-04-01 | 2014-05-14 | Univ London Queen Mary | Oncolytic virus |
| CA3004530A1 (en) * | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
-
2017
- 2017-01-11 EP EP17701004.8A patent/EP3402468B1/en active Active
- 2017-01-11 CN CN201780016755.2A patent/CN109219450A/zh active Pending
- 2017-01-11 PL PL17701004.8T patent/PL3402468T3/pl unknown
- 2017-01-11 HR HRP20231299TT patent/HRP20231299T1/hr unknown
- 2017-01-11 ES ES17701004T patent/ES2959563T3/es active Active
- 2017-01-11 RS RS20230928A patent/RS64678B1/sr unknown
- 2017-01-11 US US16/069,101 patent/US11351209B2/en active Active
- 2017-01-11 HU HUE17701004A patent/HUE063428T2/hu unknown
- 2017-01-11 WO PCT/GB2017/050051 patent/WO2017122000A1/en active Application Filing
-
2019
- 2019-01-14 HK HK19100595.8A patent/HK1258235A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109219450A (zh) | 2019-01-15 |
| EP3402468B1 (en) | 2023-07-26 |
| US20190022156A1 (en) | 2019-01-24 |
| ES2959563T3 (es) | 2024-02-27 |
| RS64678B1 (sr) | 2023-11-30 |
| WO2017122000A1 (en) | 2017-07-20 |
| HK1258235A1 (zh) | 2019-11-08 |
| PL3402468T3 (pl) | 2024-01-29 |
| EP3402468C0 (en) | 2023-07-26 |
| EP3402468A1 (en) | 2018-11-21 |
| HRP20231299T1 (hr) | 2024-02-02 |
| US11351209B2 (en) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1249524A1 (zh) | 用於治療血載癌症的免疫檢查點抑制劑 | |
| ZA201807810B (en) | Adenosine derivatives for use in the treatment of cancer | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| IL258854A (en) | Preparations containing cannabidiol and secondary medicinal agents for cancer treatment | |
| IL266198A (en) | Liposomal formulation for use in cancer treatment | |
| IL276733A (en) | Use of Aribolin in cancer treatment | |
| IL248767B (en) | Trimethoxyphenyl-benzaimidazole compounds for cancer treatment | |
| IL247586A0 (en) | Use of Aribolin and mtor inhibitors as a combined treatment for cancer | |
| IL290251A (en) | Combination for effective treatment of metastatic cancer in patients | |
| PL3253208T3 (pl) | Terapie kombinowane do zastosowania w leczeniu nowotworu piersi | |
| EP3708173C0 (en) | PHARMACEUTICAL COMPOSITION COMPRISING MIRNA-3140 FOR THE TREATMENT OF CANCER | |
| HUE058749T2 (hu) | Készítmények és módszerek homocisztinuria kezelésében történõ alkalmazásra | |
| HK1258235A1 (zh) | 在癌症治療中用於傳播病毒的PI3K P-δ110亞型抑制劑 | |
| EP3440052C0 (en) | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | |
| IL253933A0 (en) | History of pyrimidine use in the treatment of cancer | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| HK1251476A1 (zh) | 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽 | |
| IL249860A0 (en) | Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer | |
| GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment |